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Background: The epicentre of a successful pregnancy lies within the placenta and is nurtured by 
suppressed immune responses. However, the fragile balance between maternal inflammatory 
responses and the regulation of maternal immunoglobulins is distorted by HIV and Preeclampsia 
(PE). Preeclampsia and co-morbid diseases such as HIV infections are major contributors to 
maternal morbidity and mortality, worldwide. Furthermore, the effects of Highly Active 
Antiretroviral therapy (HAART) on the reconstitution of immunity in HIV preeclamptics remain 
obscure. Therefore, the current study aims to investigate the role of immunoglobulins in HIV 
infected preeclamptics and elucidate the effects of HAART on immunoglobulin levels in HIV 
infected PE. 
Method: Ethical clearance was granted by the Biomedical Research Ethics Committee (BREC). 
Serum samples of 38 normotensive and 38 preeclamptic pregnancies were collected at a regional 
hospital and further categorized based on HIV status. The serum samples were then subjected to 
the analysis of immunoglobulin (IgG1-IgG4, IgA and IgM) concentration (ng/dl). The Bio-Plex 
immunoassay technique of analysis was used to investigate the concentration of immunoglobulin 
isotypes in the sample population. Immunoglobulin concentrations were considered significant 
when p < 0.05. 
Results: Immunoglobulin concentration was evaluated in pregnancy type irrespective of HIV 
status. A non-significant down-regulated trend of IgG1, IgG3 and IgG4 was observed, whilst IgG2 
and IgM showed a non-significant up-regulation. On the contrary, IgA levels presented a 
significant increase in preeclamptics irrespective of HIV status. However, in HIV infected 
pregnancies irrespective of pregnancy type IgG1 presented a non-significant up-regulated trend, 
whilst IgG3 and IgG4 showed non-significant down-regulatory trends. Nonetheless, IgG2, IgA 
and IgM demonstrated a significant down-regulation in HIV infected pregnancies, irrespective of 
pregnancy type. Furthermore, IgG1, IgG3, IgG4 and IgM showed a non-significant difference 
when analysed according to pregnancy type and HIV status. However, IgG2 and IgA presented a 
significant up-regulation in HIV negative PE. 
Conclusion: This study highlights the importance of the maternal-fetal transfer of 
immunoglobulins (IgG subclass) in pregnancy. We report a significant up-regulation of IgG2, 
indicating its role in activating the classical complement pathway thereby, exacerbating the 
inflammatory response in PE. The up-regulation of IgA is an ingenerate anti-inflammatory 
response, which inhibits the exacerbated inflammatory cascade via classical complement 
activation in PE.  In HIV infection the down-regulation of IgG2, IgA and IgM maybe due to 
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HAART. In addition, IgA showed an up-regulation in HIV associated PE, suggesting that the 
reconstitution of HAART is insufficient in neutralizing the exaggerated inflammatory response 




































INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Maternal Mortality 
“Maternal mortality is the death of a woman whilst pregnant or within 42 days of delivery or 
termination of pregnancy, from any cause related to, or aggravated by pregnancy or its 
management, but excluding deaths from incidental or accidental causes.” 
(World Health Organization, 1992) 
 
The health of a woman during pregnancy and the puerperium is essential to the well-being of a 
society (Moran and Moodley, 2012). However, every day approximately 800 women die from 
childbirth or pregnancy related complications, worldwide (World Health Organization, 2014). 
Sub-Saharan Africa and southern Asia account for 83.8% of maternal deaths in the world (Say et 
al., 2014). According to the World Health Organization (WHO), hypertensive disorders of 
pregnancy such as preeclampsia (PE) are the most common cause of maternal mortality (2.7%), 
followed by other complications and diseases (2.5%), hemorrhagic disorders (1.1%)  and 
infectious diseases (0.6%) (Vogel et al., 2014).  
 
In South Africa, the impact of HIV infections and hypertensive disorders such as PE on maternal 
mortality prevalence rates, remain prominent (Moodley et al., 2016; Phoswa et al., 2018). 
Progress to reduce maternal mortality rates depend on competent hospital care, strong health 
systems and understanding the cause of  diseases responsible for maternal deaths (Alkema et al., 
2016). Hence, this study intends to provide data on HIV infected women with PE in, KwaZulu-
Natal, South Africa. 
 
 
1.2 Human immunodeficiency virus (HIV) 
1.2.1 The epidemiology and etiology  
First identified in the 1980’s, HIV infection has become a leading global health crisis (Gallo and 
Montagnier, 2003; Nakagawa et al., 2013). HIV has unique characteristics such as persistent 
infection, vertical transmission from mother to child, transmission through body secretions, and 
a variability that allows it to escape immunity and antiretroviral drugs (Maartens et al., 2014). 
 
It has been estimated that 13.1% South Africans are HIV positive, of whom one fifth are women 
of child bearing age (15-49 years) (Statistics South Africa, 2018). The risk of maternal death for 
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a HIV infected pregnant woman is approximately 10 times higher than that of a HIV negative 
pregnant woman (Moran and Moodley, 2012). These statistics incite research on this maternal 
epidemic in South Africa. 
 
1.2.2 The pathogenesis of HIV  
HIV exists as an enveloped glycoprotein complex that targets CD4 (T-helper cell) cell receptors 
(Lizeng et al., 2003). Once inside the target cell, HIV uses the viral enzyme-reverse transcriptase 
to produce DNA from viral RNA (Warnock et al., 2011). The new viral DNA called a provirus, 
inserts itself into the target cell’s nucleus (Cooper et al., 2013). The provirus then directs the host 
cell into producing new copies of viral RNA proteins, enabling the multiplication of HIV (Stacey 
et al., 2009).  
 
Although B cells and T-helper cells initially mount a vigorous response to viral exposure, over 
time HIV destroys these cells together with other body cells such as macrophages, monocytes, 
astrocytes and dendritic cells (Liu et al., 2004; Maartens et al., 2014). Consequently, the resultant 
profound deficit in B cells and T-helper cells have a domino effect, causing the collapse of an 
efficient immune system (Moir and Fauci, 2017). This leads to high viral mutation rates and 
changing resistance to anti-retroviral drugs (Maartens et al., 2014).  
 
 
1.3 Preeclampsia- “The disease of theories” 
1.3.1 The epidemiology and etiology 
Preeclampsia is an exaggerated inflammatory disease that occurs in almost 7-10% of all 
pregnancies and is responsible for more than 50 000 deaths /annum worldwide (Ghulmiyyah and 
Sibai, 2012; Loewendorf et al., 2015). A higher prevalence of PE is reported in low-middle 
income countries (LMIC) as opposed to developed countries,  due to the lack of robust prenatal 
care and health services (World Health Organization, 2005).  
 
Preeclampsia is typically characterized by new onset-hypertension (systolic blood pressure ≥140 
mmHg or diastolic blood pressure ≥90 mmHg) and protein excretion ≥ 300 mg in 24 hours, within 
20 weeks of gestation (Hutcheon et al., 2011). This pregnancy specific disorder involves multiple 
organ systems including the kidney, liver, lungs, heart, pulmonary and neurological systems 
(Young et al., 2010; Arulkumaran and Lightstone, 2013). In addition, PE may lead to the 
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development of eclampsia, fetal growth restriction and low birth weight babies (Ghulmiyyah and 
Sibai, 2012; Gathiram and Moodley, 2016). 
 
Despite being the primary reason for intensive care unit admittances during the puerperal period, 
the multifactorial etiology of PE remains unclear (Khaliq et al., 2018). However, various risk 
factors for PE have been reported (Phoswa et al., 2018). According to Mol et al. (2016) a maternal 
or paternal family history of PE, maternal age, obesity and multiple pregnancies predispose 
women to PE. Similarly, women who suffer from pre-existing conditions such as chronic 
hypertension, autoimmune disease, kidney disease or infertility are at a higher risk of developing 
PE (Uzan et al., 2011). In addition, the primi-paternity hypothesis states that the risk of PE 
increases in women with limited exposure to their partners sperm (Hutcheon et al., 2011).  
 
1.3.2 Placental origins of normotensive pregnancies 
During early human pregnancy a depressed maternal immune system causes extra villous 
cytotrophoblasts to invade the uterus (Naicker et al., 2013). This invasion transforms spiral 
arteries into large sinusoidal-like vessels of low resistance thus enhancing placental perfusion to 
meet the utero-placental unit’s metabolic demands (Whitley and Cartwright, 2010). The 
transformation of these vessels are referred to as the physiological re-modelling of spiral arteries 
(Harris, 2011). 
 
1.3.3 Placental origins and pathogenesis of preeclampsia  
The pathogenesis of PE remains surreptitious thus its name “the disease of theories” (Pipikin and 
Rubin, 1994). However, few would deny that the fundamental cause of PE involves the placenta 
(Jeffocate, 1966). In PE, endovascular invasion of the uterus is limited to the decidua, (Lyall et 
al., 2013). Therefore, physiological re-modelling of spiral arteries in the myometrium is 
ineffective (Cerdeira and Karumanchi, 2012). This results in smaller myometrial arterial 
diameters, eventuating in trophoblast cell death (Young et al., 2010). Consequently, the death of 
trophoblast cells create a hypoxic environment for the placental and fetal tissue (Huang et al., 
2010). These abnormalities allow the interaction between activated immune cells and pro-
inflammatory cytokines to persist (Shamshirsaz et al., 2012). This eventuates in placental 




Many studies attribute trophoblast cell death to immunological factors such as a deviant 
immunologic tolerance to pregnancy, exaggerated inflammatory responses, increased circulating 
anti-angiogenic factors, the perturbation of the renin-angiotensin axis II and decreased placental 
nitric oxide production (Venkatesha et al., 2006; Matsubara et al., 2015). Whist other studies 
hypothesize that genetic susceptibility to aberrant placentation is the cause of PE. (Thakoordeen 
et al., 2018). Despite the innumerable pathogenic theories, PE remains incurable and the only 
recognized treatment is delivery of the placenta (Young et al., 2010). 
 
1.3.4 The role of inflammation and oxidative stress in preeclampsia  
Pregnancy poses a metabolic and immune challenge for the mother who must accommodate a 
semi-allogenic fetus (Kalagiri et al., 2016). During healthy pregnancy a subdued maternal 
immune system elicits a placental production of immunomodulatory hormones, anti-
inflammatory cytokines and moderated pro-inflammatory cytokines into the maternal blood 
stream (Cornelius et al., 2018). This in turn suppresses the inflammatory cascade, to avoid 
rejection of the fetus, whilst simultaneously protecting maternal immunity and apposite 
placentation (Eiland et al., 2012; Harmon et al., 2016). These immunomodulatory hormones and 
cytokines also act as mediators of morphologic changes during spiral artery conversion (Ducray 
et al., 2011). 
 
However, since PE is associated with an exaggerated inflammatory cascade, an amplified 
placental production of pro-inflammatory cytokines transpires (Boij et al., 2012). This impairs 
the regulation of arterial supply systems, cytotrophoblast invasion and endovascular proliferation 
in the placenta (Harmon et al., 2016). The aberrant production of  pro-inflammatory cytokines 
instigates an oxidative burst from Reactive Oxygen Species (ROS), which exceed their 
antioxidant capacity (Shamshiraz et al., 2012). Thereby, resulting in vascular oxidative stress 
during PE (Bowen et al., 2001). This in turn, enhances hypoxia in fetal and placental tissues 
(LaMarca et al., 2007). Therefore, it is believed that a disturbance of the maternal immunologic 
system exacerbates a chronic inflammatory cascade, which may lead to pregnancy loss during PE 
(Ahmad and Khidir, 2018; Black and Horowitz, 2018). 
 
 
1.4 Impact of HIV on the incidence of Preeclampsia  
One of the pathogenic explanations for PE development, is the aggravation of the maternal 
immune tolerance to pregnancy (Kalumba et al., 2013). However, HIV infection is associated 
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with immune suppression (Browne et al., 2015). Therefore, it has been postulated that HIV 
infection would inhibit immune hyperactivity and thus prevent the development of PE (Frank et 
al., 2004). However, PE research among HIV-infected women are limited (Powis et al., 2013). 
There is ongoing debate as to whether HIV-infected women have a lower or higher susceptibility 
to developing PE, compared to HIV negative women (Landi et al., 2014). Furthermore, the use 
of Highly Active Anti-Retroviral Therapy (HAART) in HIV infected individuals has been 
proposed to reestablish excessive immune responses (Landi et al, 2014). Therefore, it is has been 
hypothesized that HAART may predispose HIV infected pregnant women to PE development 
(Phoswa et al., 2018). 
 
 
1.5 Immunoglobulins  
1.5.1 Mechanism of action in the human immune system 
Humans have a sophisticated immune system, which includes several types of immune cells and 
an array of specialized protein molecules (Holborow and Reeves, 1977). These proteins belong 
to a specific group of antibodies known as immunoglobulins, that are produced by B cells or 
plasma cells (Berkowska et al., 2011). In 1939, immunoglobulin G (IgG), immunoglobulin A 
(IgA) and immunoglobulin M (IgM) were discovered as three patently recognized groups of 
proteins (Schroeder and Cavacini, 2010). A few decades  later, immunoglobulin D (IgD) and 
immunoglobulin E (IgE) antibody isotypes were discovered (Amarasekera, 2011; Chen and 
Cerutti, 2011). Immunoglobulins defend the immune system as natural antibodies, through 
antigen-antibody interactions (Zhou et al., 2007). These complexes inactivate antigens via their 
direct neutralization, agglutination, precipitation, lysis, phagocytosis and indirect complement 




Figure 1.1: Mechanism of antibody action in human immunity-Adapted from Marieb and Hoehn, (2007). 
 
1.5.2 The structure of immunoglobulins 
In humans, there are five immunoglobulin classes: 
 
• α – IgA 
• δ – IgD 
• γ – IgG 
• ε – IgE 
• μ – IgM 
 
Immunoglobulins are composed of 82-96% proteins and 4-18% carbohydrates (Vidarsson et al., 
2014). These globulins have molecular weights between 160 000 and 970 000 kDa (Marieb and 
Hoehn, 2007) . All immunoglobulins have a similar basic structure consisting of four looping 
peptide chains with disulfide  bonds, which form a molecule known as an antibody monomer 
(Williams and Barclay, 1988; Malek, 2013). These monomers structurally take up either a Y or T 




Figure 1.2: Schematic diagram of a typical antibody showing two Ig heavy chains (yellow) linked by 
disulfide bonds to two Ig light chains (blue)-Adapted from Schroeder and Cavacini, (2010). 
 
One half of the four chains are heavy chains, whilst the other half are light chains (Williams and 
Barclay, 1988). Immunoglobulin isotypes have different heavy chain regions and effector 
functions (Leder, 1982; Tonegawa, 1983). Both heavy and light chain regions are divided based 
on the variability in their amino acid sequence (Schroeder et al., 2008). These are the: 
 
o Light Chain – Variable region (110 amino acids) and Constant region (110 amino acids). 
o Heavy Chain – Variable region (110 amino acids) and Constant region (330-440 amino 
acids). 
 
Each chain that forms an antibody has a variable (V) region at one terminal, and a constant (C) 
region at the opposite terminal (Casali and Schettino, 1996). These variable regions form the 
antigen-antibody binding sites (Schroeder and Cavacini, 2010). The expression of a specific 
isotype determines the function of an antibody, via the specific binding to Fc receptor molecules 
on different isotype cells (Smith et al., 2004). 
 
1.5.3 The role of complement fixation in inflammation 
Complement fixation is the chief antibody defense mechanism employed against foreign cell 
agents in the body (Nayak et al., 2010). Complement activation occurs via three pathways each 
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activated by specific antibody or antigen complexes viz: classical, lectin and alternative pathways 
(Regal et al., 2015). The systemic action of the classical pathway is activated through the binding 
of immunoglobulins (IgG subclasses and IgM) to antigen cells, and then to C1 complement 
molecules (Nayak et al., 2010). However IgG2 and IgG4 activate classical complement less 
efficiently and only under certain conditions (Vidarsson et al., 2014). The lectin pathway is 
activated by antibody binding to mannose-binding lectin (MBL) molecules, whereas, the 
alternative pathway does not require an exogenic trigger, and is activated at low levels (Collard 
et al., 2000; Carroll, 2004).  
 
Essentially, all three pathways lead to the deposition of C3b to further opsonize the target and 
form membrane attack complexes -C5-C9  (Figure 1.3) (Regal et al., 2015). Many of the proteins 
released from the complement pathway are enzyme precursors (Nayak et al., 2010). The release 
of these proteins amplify the inflammatory response, and promotes phagocytosis, cell lysis and 
anomalous placental development, during pregnancy (Shamshirsaz et al., 2012).  
 
 
Figure 1.3: The Antigen-Antibody complex during the activation of the classic pathway of complement- 




1.5.4 Immunoglobulin isotypes and their biological roles in humans  
IgM: Immunoglobulin M is the first immunoglobulin to be released by plasma cells as a primary 
response to pathogen invasion and is indicative of a current infection (Gronwall et al., 2012). IgM 
is a good agglutinating agent and is produced in considerable serum quantities in humans (400-
2300 µg/ml) (Wang et al., 2016). If prolonged high levels of this immunoglobulin exist, then a 
prolonged exposure to parasites may be assumed (Raccine and Winslow, 2009). 
 
IgG: Immunoglobulin G is the secondary protective action that occurs against a foreign antigen, 
and it is the most abundant serum protein in humans (Vidarsson et al., 2014). This specific 
immunoglobulin isotype contains four subclasses such as IgG1, IgG2, IgG3 and IgG4, that are 
named according to their decreasing levels within human serum (Einarsdottir et al., 2014). 
Although the IgG subclasses have identical amino acid sequences, each subclass consists of 
different constant regions, that are involved in binding to IgGFc receptors (FcγR) and C1 
molecules of classical complement (Vidarrsson et al., 2014). This results in different effector 
functions amongst the subclasses, regarding activation of the complement pathway, phagocytosis 
or antibody-dependent cell-mediated cytotoxicity (Kapur et al., 2014). The activation of a specific 
subclass is sometimes dependent on the specificity of the antigen present (Vlug et al., 1994; Pan 
and Hammarstrom, 2000). The chemical composition of the antigen may also cause preferential 
subclass switching within the IgG group  (Pone et al., 2010; Pone et al., 2012). In addition, 
selective subclass deficiencies are not detrimental, but they may lead to an enhanced susceptibility 
towards specific pathogenic classes (Jefferis and Kumararatne, 1990). 
 
IgA:  Immunoglobulin A is abundant in human body secretions such as saliva, sweat, intestinal 
juice and milk (Lopez et al., 2018). However, serum IgA exists in limited amounts in plasma, and 
accounts for 20%  of all serum immunoglobulins (Pabst, 2012). Therefore, secretory IgA  and 
serum IgA are molecules with different biochemical and immunochemical properties (Kerr, 
1990). IgA functions to thwart pathogenic  attachment to epithelial cell surfaces (including neuron 
membranes and the epidermis), it is also believed that IgA may possess anti-inflammatory effects 
(Woof and Russell, 2011). 
 
IgD: Immunoglobulin D represents  0.25% of the total immunoglobulins in human serum 
(Rogentine et al., 1966). Despite its discovery five decades ago, the specific function of IgD 




IgE: The immunoglobulin E isotype protects the host from parasitic infections that induce 
allergies (Amarasekera., 2011; Xiong et al., 2012). In human blood IgE exists in trivial quantities, 
unless stimulated by allergic antigens (Unal et al., 2017). During allergic reactions IgE binds to 
the surface membrane of blood basophils and tissue mast cells (Fish et al., 2005). It is believed 
that IgE evolved to protect the host from helminth infections (Snow et al., 1996). 
 
1.5.5 Placental transfer of maternal immunoglobulins to the fetus 
An undeveloped fetal immune system requires immune protection from the maternal-to-fetal 
transfer of antibodies across the placenta (Simister, 2003). During pregnancy, the predominant 
antibody in the maternal-fetal transport process is IgG and its subclasses (Kane and Acquah, 
2009). The concentration of IgG and its subclass in a maternal-to-fetal direction is regarded as: 
IgG1> IgG4> IgG3> IgG2 (Malek, 1996). The placental transfer of IgG and its subclasses depend 
on maternal levels (Palmeira et al., 2011). Nonetheless, existing IgM in the fetus is of fetal origin, 
whilst no transfer activity of IgA in the maternal-to-fetal placental transfer mechanism has been 
reported to-date (Malek, 2013).  Relatedly, IgD and IgE isotypes have not been reported in this 
transfer process (Holt and Jones, 2000). Therefore, the current study involves the detection of 
antibodies, specifically IgG1, IgG2, IgG3, IgG4, IgA and IgM in maternal serum. 
 
 
1.6  The role of immunoglobulins in normotensive pregnancies 
During healthy human pregnancy, complement activation  produces a judicious inflammatory 
response that succors the continuation of pregnancy (Salmon and Girardi, 2008). However, the 
role of immunoglobulins in activating a suppressed complement cascade has yet to be fully 
elucidated (Nayak, et al., 2010). Khirwadkar and Kher (1991) studied IgG, IgA and IgM levels in 
healthy pregnant women compared to non-pregnant women. Healthy pregnant women reported a 
decrease in IgG and IgA, throughout pregnancy although, IgM appeared to increase in the third 
trimester (Khirwadkar and Kher, 1991).  
 
 
1.7 The role of immunoglobulins in preeclampsia 
Preeclampsia involves the maladaptation of the maternal immune system, which results in a 
hyperbolic complement activation and systemic inflammatory response (Derzy et al.,  2010). This 
is sequentially associated with placental insufficiency, maternal endothelial dysfunction and fetal 
growth restriction  that is characteristic of PE (Lynch and Salmon., 2010). 
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A few studies have investigated the role of antibodies in the heightened inflammatory response 
of PE (Arinola et al., 2006; bAmah-Tariah et al., 2016). A significantly lower IgG level in 
preeclamptic pregnancies have been reported (Fialova et al., 2004; bAmah-Tariah et al., 2016). In 
contrast, Biró et al. (2007) reported no significant differences in IgG levels during PE. In addition,  
no significant difference in IgM concentrations have been reported between normotensive and 
preeclamptic pregnancies (Fialova et al., 2004; Arinola et al., 2006). However, data on IgM levels 
in PE are variable, as bAmah-Tariah et al. (2016) reported significantly lower levels in 
preeclamptic, diabetic Nigerian women with significantly higher IgA levels in preeclamptic 
pregnancies (Arinola et al., 2006). 
 
 
1.8 The role of immunoglobulins in HIV infected pregnancies  
The consequence of HIV infection on the human immune system, is progressive 
immunodeficiency (Huber et al., 2011). This deficiency leaves the body vulnerable to pathogens 
and opportunistic malignancies (Josh et al., 2011). Over-time HIV destroys the antibody immune 
response, through the depletion of CD4 T-cell count and the impairment of B cell function 
(Prendergast et al., 2010; Cooper et al., 2013).  Subsequently, HIV infection during pregnancy 
may result in aberrant immunoglobulin levels, dysregulated compliment activation and cell-
mediated immunity, which disturbs the precarious immune state in pregnancies (Khan et al., 
2016). 
 
 However, a Nigerian study has reported that HIV viral load and serum immunoglobulin 
concentrations have no statistically significant correlations, irrespective of pregnancy (Akinpelu 
et al., 2012). Conversely, HIV infection is known to impair B lymphocyte activity with a resultant 
increase in overall immunoglobulin levels (Aucouturier et al., 1986). In a recent study, aAmah-
Tariah et al. (2016) assessed immunoglobulin levels in HIV positive pregnant women with 
malaria and reported an overall increase in IgG, IgM and IgA levels over the three trimesters of 
pregnancy. The increase in immunoglobulin levels may lead to adverse pregnancy outcomes 





1.9 The role of immunoglobulins in HIV infected preeclampsia 
Preeclampsia is a gestational precondition that involves the hyperactivity of the immune system 
and inflammatory mechanisms, whilst HIV eventuates in a chronic inhibition of the immune 
system (Akinpelu et al., 2012; Harmon et al., 2016). 
 
The significant decrease of IgG levels during PE could be explained by the placental transfer of 
immunoglobulins, or proteinuria loss of IgG subclasses (aAmah-Tariah et al., 2016). However, 
elevated IgG levels in HIV infected pregnancies may be the result of increased B cell activation 
to control the high viral load (Akinpelu et al., 2012). Furthermore, the maternal decrease of IgA 
and IgM may be attributed to significant proteinuria loss during PE (Arinola et al., 2006). 
Nevertheless, damage to the vascular walls in PE, initiates intense narrowing of blood vessels, 
resulting in placental ischemia (Eiland et al., 2012). This leads to an increased production of white 
blood cells and IgM antibodies, which mount a rapid stimulation of inflammatory responses, 
possibly validating the conflicting IgM increase in PE  (aAmah-Tariah et al., 2016). 
 
In addition, increased IgA levels during pregnancy may be result of a fostered neutralization 
activity against antigens during PE or HIV infection (aAmah-Tariah et al., 2016). Similarly, 
increased IgM levels may signify existing pathogenic activity, and HIV disease progression 
(aAmah-Tariah et al., 2016). 
 
 Despite the few studies on immunological parameters in South Africa,  there is a paucity of data 
on the effects of immunoglobulins in HIV infected preeclamptics. Therefore, this study aims to 
investigate immunoglobulin isotypes in HIV associated preeclamptics receiving HAART in a 
South African setting. 
 
 
1.10 Aims and objectives  
The exploration of serum markers in HIV infected pregnant women on HAART and PE, steer the 
direction of research on preventative strategies. The fundamental objective behind such studies is 
the global need to improve overall antenatal and perinatal care. Therefore, this study targeted the 
response of immunoglobulins in immune activation, which prompt the release of pro-









• To analyse the concentration of IgG subclasses, IgA and IgM,  and examine their role in 
inflammatory responses based on pregnancy type (Normotensive pregnant vs PE) and 
HIV status (HIV negative vs HIV positive).  
 
• To analyse the concentration of IgG subclasses, IgA and IgM, and evaluate their role in 
immune responses during HIV associated PE.  
 
• To examine the effect of HAART on the concentration of IgG subclasses, IgA and IgM 
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The fragile balance of immunity that exists in pregnancy is altered during pregnancy 
complications, such as preeclampsia and HIV infection. Immune responses are 
coordinated by the regulation of immunoglobulins, which is dysregulated during 
pregnancy. Preeclampsia involves the exacerbation of an immune response. However, 
HIV infection suppresses the immune system. This study aims to elucidate the role of 
immunoglobulins in HIV associated normotensive versus preeclamptic pregnancies, 
receiving HAART. Post informed consent, 38 normotensive and 38 preeclamptic women 
were sub-categorised by HIV status. Maternal serum was analysed using the Bio-Plex 
immunoassay technique. IgA was significantly up-regulated in PE compared to 
normotensive pregnancies. Additionally, IgG2, IgA and IgM were significantly down-
regulated in HIV positive pregnancies. IgG2 and IgA expressed significant up-regulations 
in HIV negative PE. The significant difference of IgG2 and IgA suggest an association 
between the hyper-inflammatory milieu of PE and HIV infection in neutralising 
immunity, irrespective of HAART.  
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The epidemiology of the Human immunodeficiency virus (HIV) infection and 
hypertensive disorders such as preeclampsia (PE), implicate both disorders as 
major contributors to maternal mortality in South Africa (Maharaj et al., 2017). 
However, global prevalence data on PE among HIV infected pregnant women 
remain discrepant (Machado et al., 2014). 
Preeclampsia is defined as a multi-organ hypertensive disorder of pregnancy, that 
is associated with a generalized systemic inflammatory response (Wu et al., 
2017). The etiology of PE is unclear therefore, treatment remains empiric (Khaliq 
et al., 2018). The modern understanding of the pathogenesis of PE involves the 
exploration of possible alterations in immunological processes (Maharaj et al., 
2017). 
During healthy pregnancy, a suppressed immune response evades maternal 
rejection of the fetal allograft thereby, ensuring pregnancy success (Kalagiri et al., 
2016). However, in PE a decreased cytotrophoblast invasion, is followed by a 
resultant non-physiological transformation of myometrial spiral arteries 
(Thakoordeen et al., 2018). This leads to the development of small-bore high 
resistance capacitance vessels with  reduced blood flow, creating a hypoxic 
microenvironment that contributes to maternal morbidity and mortality (Redman 
and Sargent, 2009; Costantine and Cleary, 2013). Moreover, an activation of pro-
inflammatory cytokines, exacerbates the inflammatory cascade in PE (Cornelius 
et al., 2018). 
In addition, HIV infection involves cell invasion by the virus, to produce viral 
RNA (Maartens et al., 2014). This enables the multiplication of HIV and 
eventually results in the destruction of T-helper and B cells (Stacey et al., 2009; 
Cooper et al., 2013). The efficient production of antibodies is thus distressed 
causing a suppression of the immune system and exposing cells to opportunistic 
viral infections (Huber et al., 2011). 
The role of the immune system is fundamental to both PE development and HIV 
infection (Girardi et al., 2006; Landi et al., 2014). Therefore, knowledge on 
antibody activation of the immune inflammatory response is pertinent, when 
attempting to understand the pathophysiology and treatment of both PE and HIV 
infection. 
Immunoglobulins are a group of antibody cells produced by B cells, that activate 
the complement pathway (Ziegler et al., 2018). Immunoglobulin activation of the 
classical complement pathway initiates cell lysis, phagocytosis of foreign antigen 
cells and inflammatory responses (Shamshirsaz et al., 2012). During healthy 
pregnancy, the maternal-fetal placental transfer of immunoglobulins 
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simultaneously contributes to the suppression of the immune system and 
protection of the fetus (Fouda et al., 2018). Immunoglobulin G (IgG) and its 
subclasses are the predominant immunoglobulin in the maternal transmission of 
antibodies (Holt and Jones, 2000). Despite the role of IgM and IgA in the 
complement pathway, these immunoglobulins are omitted from the maternal-fetal 
transfer of immunity (Malek, 2013). 
In PE, a significant decrease in the concentration of IgG with a concomitant 
increase in IgA and IgM have been reported (Arinola et al., 2006). In contrast, 
Biró et al. (2007) observed no significant difference in IgG and IgM levels 
between preeclamptic compared to normotensive healthy pregnancies. Therefore, 
data on immunoglobulin concentrations in PE are conflicting (Table 1).  
Nonetheless, a significant increase in IgG, IgA and IgM was observed in HIV 
positive pregnancies (aAmah-Tariah et al., 2016). 
To our knowledge, there is no available data on immunoglobulin isotype levels in 
HIV associated normotensive and preeclamptic pregnancies. Moreover, there is a 
paucity of data on immunoglobulin levels in HIV infected pregnancies receiving 
HAART. Therefore, the aim of this study is to investigate the concentration of 
immunoglobulin isotypes (IgG1-IgG4, IgA and IgM) in HIV infected women 
with PE, receiving HAART. 
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Table 1: Immunoglobulin concentrations in normotensive, preeclamptic and HIV infected pregnancies, extracted from previous studies. 
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METHODS AND MATERIAL  
 
Ethics approval and study population 
 
This prospective study was conducted at the University of KwaZulu-Natal. 
Institutional ethics clearance was obtained from the Biomedical Research Ethics 
Committee (BREC-BE 338/17). Participants were recruited in the antenatal 
period (trimesters 2 and 3) from a large regional hospital in Durban, South Africa. 
The study population (n=76) was determined in consultation with a biostatistician 
using the Fischer’s test, and consisted of a normotensive group (n=38) and a PE 
group (n=38). Each group was further categorized into HIV positive (n=19) and 
HIV negative (n=19) women. Following written informed consent, venous blood 
samples were collected in K3-EDTA tubes, serum was then extracted and stored 
in cryovials at -80°C, until immunoassay. PE was defined as a systolic pressure 
(mmHg) of ≥140 and a diastolic pressure ≥90 (mmHg), whilst proteinuria 
measured ≥2 on a urine dipstick after 20 weeks of pregnancy (Cnossen et al., 
2006). All diagnosed HIV positive women were initiated on anti-retroviral 
therapy (HAART). Healthy normotensive and HIV negative pregnant women 
served as control groups. The exclusion criteria were based on pregnant women 
with: chorioamnionitis, eclampsia, polycystic ovarian syndrome, abruptio-
placentae, intrauterine death, sickle cell disease, chronic renal disease, cardiac 




Differences in serum immunoglobulin isotypes were assessed using the Bio-Plex® 
Pro™ Human isotyping Panel 6-Multiplex assay (catalogue #171A3100M; Bio-
Rad laboratories Inc., South Africa) according to the manufacturer’s instructions. 
Serum IgG1-IgG4, IgA and IgM (1:40 000 dilution) were distinguished by capture 
antibody-coupled magnetic beads. This immunoassay was similar to the sandwich 
ELISA technique. Fluorescent SA-PE was used to bind and  capture antibody-
coupled magnetic beads. After washing, detected differences in fluorescent 
intensity and concentration of captured coupled magnetic beads of the serum 
isotypes were carried out, using Bio-Plex® MAGPIX™ Multiplex Reader (Bio-
Rad laboratories Inc, USA). 
The Bio-Plex Manager™ software version 4.1. was used to obtain the observed 
concentration of serum immunoglobulin isotypes based on pregnancy type 
(normotensive vs PE) and HIV status (HIV negative vs HIV positive).  
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Statistical Analysis   
Data was analyzed using GraphPad Prism 5.00 for windows (GraphPad Software, 
San Diego, California USA). Statistical analysis across all groups, HIV status and 
pregnancy type were performed using the One-way ANOVA (Bonferroni post hoc 
and Kruskal Wallis) multiple comparison tests. For individual analysis, a student’s 
T-test was performed. The level of significance was considered as a probability 























Patient demographics (maternal age, gestational age, systolic pressure, diastolic 
pressure and weight) are outlined in Table 2. 
 


















Maternal age (years) 25.32±5.76 28.00±6.37 28.53±6.66 29.95±6.23 0.1517 
Gestational age (weeks) 38.42±1.87 39.44±1.82 28.11±2.26 28.21±2.26 0.0001 
Systolic BP (mmHg) 113.26±12.09 120.70±10.59 159.42±12.35 155.84±8.90 0.0001 
Diastolic BP (mmHg) 70.89±8.87 72.65±9.90 101.32±8.90 105.05±11.96 0.0001 
Maternal weight (kg) 78.02±15.38 77.36±12.95 72.52±16.68 75.66±18.10 0.5593 
Results are represented as mean ± standard deviation. Key: mmHg-millimeter mercury, Kg-kilogram, BP-
blood pressure.   
 
Table 3: Concentration of immunoglobulins between preeclamptic and normotensive 
pregnancies.  
Results are represented as mean ± standard deviation (ng/dl) 
 
         Table 4: Concentration of immunoglobulins between HIV positive and HIV negative 
pregnancies.  













IgG1 IgG2 IgG3 IgG4 IgA IgM 
Pre-eclampsia 323.90±163.70 187.20±129.60 34.39±18.92 11.34±10.95 131.20±121.60 80.11±66.07 
Normotensive 377.50±178.70 163.10±127.00 40.92±31.91 19.21±21.55 65.10±33.63 66.11±32.34 
P-value 0.2965 0.3062 0.7278 0.2531 0.0245 0.6969 
HIV status IgG1 IgG2 IgG3 IgG4 IgA IgM 
HIV positive 366.90±191.50 128.30±81.87 36.42±30.25 12.65±14.88 74.21±68.62 61.05±41.53 
HIV negative 334.60±151.70 222.00±148.40 38.89±21.90 17.90±19.51 122.10±110.80 85.18±59.06 
P-value 0.4175 0.0011 0.1819 0.1487 0.0038 0.0176 
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Table 5: Concentration of immunoglobulins between four subject groups inclusive of 
HIV status and pregnancy type.  
Results are represented as mean ± standard deviation (ng/dl) 
 
Immunoglobulins in pregnancy type:  
Table 3 outlines the mean ±standard deviation (ng/dl) of immunoglobulins based 
on pregnancy type i.e. pre-eclamptic vs normotensive pregnancies. A significant 
up-regulation of IgA was observed in PE (131.20±121.60 ng/dl) compared to 
normotensive (65.10±33.63 ng/dl) (p < 0.05) pregnancies, regardless of HIV 
status. However, no significant difference was noted for IgG1-IgG4 and IgM (p > 
0.05) based on pregnancy type.  
 
Immunoglobulins in HIV status specific pregnancy:  
The immunoglobulin expression between HIV positive vs HIV negative 
pregnancies, irrespective of pregnancy type is shown in Table 4. The expression 
of IgG2 (128.30±81.87 vs 222.00±148.40 ng/dl), IgA (74.21±68.62 vs 
122.10±110.80 ng/dl) and IgM (61.05±41.53 vs 85.18±59.06 ng/dl) was 
significantly downregulated in HIV positive compared to HIV negative 
pregnancies (p < 0.05). However, IgG1, IgG3 and IgG4 expressions were similar 
between HIV positive vs HIV negative women (p > 0.05).  
 
Immunoglobulins across all subject groups inclusive of HIV status and 
pregnancy type: 
 Table 5 shows the mean ± standard deviation (ng/dl) of immunoglobulin (IgG1-
IgG4, IgA and IgM) concentrations across all subject groups. The elevated trends 
of IgG1 and IgG3 (418.20±198.30 and 43.80±37.99 ng/dl) was noted in HIV 
positive normotensive pregnancies respectively, albeit non-significantly (p > 
0.05).  IgG2 and IgG4 levels showed highest in HIV negative PE and 
normotensive pregnancies (242.80±137.80 and 23.49±24.15 ng/dl) respectively, 
HIV status & 
pregnancy 
type 
IgG1 IgG2 IgG3 IgG4 IgA IgM 
HIV positive 
Preeclampsia 
315.60±174.60 131.60±94.97 29.03±17.97 10.36±10.54 94.80±87.82 61.10±50.58 
HIV negative 
Preeclampsia 
332.30±156.40 242.80±137.80 39.74±18.77 12.31±11.55 167.80±141.02 99.13±75.17 
HIV positive 
Normotensive 
418.20±198.30 125.00±68.81 43.80±37.99 14.94±18.25 53.61±32.75 61.00±31.42 
HIV negative 
Normotensive 
336.80±151.10 201.30±159.30 38.03±25.14 23.49±24.15 76.60±31.20 71.22±33.28 
P-value 0.6533 0.0084 0.3653 0.2770 0.0008 0.0758 
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compared to HIV positive normotensive and preeclamptic pregnancies. IgG2 
showed significance across all groups (p < 0.05), whilst no significance in IgG4 
levels existed across the groups (p > 0.05). IgA and IgM were higher in HIV 
negative preeclamptic pregnancies (167.80±141.02 ng/dl and 99.13±75.17 ng/dl) 
than in HIV negative normotensive, and HIV positive normotensive and 
preeclamptic pregnancies. However, IgM showed no significant difference 
amongst the groups (p > 0.05) whilst, IgA showed a significant difference across 


























Pregnancy is a complex journey with intricate transitional developments in the 
immune system of the mother, ensuring a successful pregnancy (Regal et al., 
2015). Immunoglobulins play an important role in maintaining the balance of the 
immune system between mother and child (Malek et al., 1994). During 
pregnancy, IgG and IgM activate the classical complement pathway, initiating a 
depressed placental production of pro-inflammatory cells and cytokines (Panda 
and Ding, 2015; Khan et al., 2016). This induces a suppressed inflammatory 
response to assure a successful pregnancy (Cornelius et al., 2018). However, the 
role of IgA in complement activation is controversial (Wolf et al., 1994). Some 
studies observed no effect on the complement pathway, whilst others highlight 
that IgA is active only in the alternative and lectin complement pathways 
(Mestecky and McGhee, 1987; Russell et al., 1989). In a study in India, healthy 
pregnant women expressed a significant decrease in IgG and IgA, with an up-
regulation of  IgM when compared to healthy non-pregnant women (Khirwadkar 
and Kher, 1991) (Table 1).   
Despite literature validating the disparity in immune levels amongst healthy 
pregnant and non-pregnant women, the immune system is further modified in 
severely complicated pregnancies (Kalagiri et al., 2016). Our study report IgG 
subclasses, IgA and IgM levels in HIV seronegative normotensive pregnancies, 
and compares them to HIV positive normotensive pregnancies and HIV positive 
and negative PE. Preeclampsia is associated with inflammatory processes 
(Fialova et al., 2004). Classical complement activation during PE suggests a 
proliferated production of pro-inflammatory cytokines that induce chemotaxis, 
leukocyte and neutrophil activation thus intensifying the inflammatory cascade 
(LaMarca et al., 2007; Khan et al., 2016). Fialova et al. (2004),  Arinola et al. 
(2006) and later, bAmah-Tariah et al. (2016) reported significantly low total IgG 
levels in PE, compared to normotensive pregnancies (Table 1). Nevertheless, in 
our study IgG1, IgG3 and IgG4 were non-significantly down-regulated in PE 
compared to normotensive pregnancies, irrespective of HIV status (Table 3). 
These results corroborate the total IgG level observed by Biró et al. (2007).  This 
diminution may be attributed to the role of IgG subclasses in the transfer of 
passive immunity from mother to child (Kane and Acquah, 2009). The 
concentration of IgG subclasses in both mother and child exists as: IgG1> IgG4> 
IgG3> IgG2 (Firan et al., 2001). Therefore, IgG1, IgG3 and IgG4 conveyed a 
down-regulation in PE.   
In our study, IgG2 was up-regulated in PE compared to normotensive pregnancies 
irrespective of HIV status, albeit non-significantly (Table 3). The increase of this 
specific subclass may be due to IgG2 being the least favored  IgG subclass 
transported across the placenta (Malek et al., 1996). Increased IgG2 levels in PE 
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could also be a result of subclass switching, that depends on the chemical 
composition and route taken by an antigen on entering the body (Berkowska et 
al., 2011). Polysaccharide antigens trigger subclass switching to IgG2, activating 
classical complement and inducing the inflammatory cascade, when T-cell help 
is unavailable (Pone et al., 2010). The IgG2 subclass also responds to bacterial 
antigens thus excessive levels of this subclass may be indicative of bacterial 
infections (Kuijpers et al., 1992). Pregnant women also have a greater 
susceptibility to infections, due to a marginally suppressed immunity (Arinola et 
al., 2006). Therefore, immunizations against communicable bacteria may increase 
IgG2 levels in pregnant women.   
In the present study, IgA was significantly increased in PE compared to 
normotensive pregnancies, irrespective of HIV status (Table 3). Nonetheless,  
bAmah-Tariah et al. (2016) noted a non-significant up-regulated trend of IgA 
levels in preeclamptic and diabetic pregnancies, compared to normotensive 
pregnancies (Table 1). Notably, an up-regulated IgA expression could be a result 
of an underlying pathogenic condition, as IgA acts to neutralize mucosal 
pathogens (Kilian and Russell, 2015). Furthermore, IgA may act to prevent 
exaggerated inflammatory responses via the lectin and alternative pathways (Wolf 
et al., 1994; Pasquier et al., 2005). IgA acts to compete with IgG and IgM 
antibodies for the same antigen, thus preventing IgG and IgM from binding to the 
C1 complex and inhibiting the classical complement activation (Wilton, 1978). 
Moreover, serum IgA appears to initiate a down-regulation of pro-inflammatory 
cytokines thus suppressing the inflammatory cascade (Wolf et al., 1994). This 
specific effector function of IgA might justify the high serum levels shown in 
hyper-inflammatory PE. Contrastingly, Arinola et al. (2006) reported 
significantly low IgA levels in PE when compared to normotensive pregnancies 
(Table 1). The down-regulation of IgA may be explained by significant 
proteinuria loss that occurs during PE, as a result of increased glomerular filtration 
or reduced reabsorption (Murakami et al., 2000).   
In the current study, IgM levels were up-regulated (albeit non-significantly) in PE 
compared to normotensive pregnancies, irrespective of HIV status (Table 3). 
Consistently, previous studies also report a non-significant up-regulation in IgM 
levels in PE (Fialova et al., 2004; Arinola et al., 2006; Biró et al., 2007). 
Nonetheless, bAmah-Tariah et al. (2016) observed a significant up-regulation of 
IgM in PE versus normotensive pregnancies (Table 1). IgM antibodies are the first 
line of defense in pathogenic invasion hence, underlying infections such as the 
HIV infection may explain the observed upregulation (Wang et al., 2016). IgM is 
also a principal activator of the C1 complex in classical complement and may be 
increased during PE (Ziegler et al., 2018). Moreover, IgA and IgM are omitted 
from the maternal-fetal immune transfer hence, the observed up-regulation of 
these immunoglobulins (Malek, 2013; Rakoff-Nahoum, 2016).  
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HIV infected pregnant women undergo severely complicated pregnancies, as the 
immune system is directly affected and modified by the virus itself (Huber et al., 
2011). Initially direct activation of classical complement by HIV remains 
complex however, the immune system induces neutralization mechanisms to 
reduce viral infectivity (Scherl et al., 2006).  In line with the latter, an up-regulated 
trend of IgG1 was noted in HIV infection, albeit non-significantly (Table 4). 
Nevertheless, a significant increase of total IgG in HIV infected pregnant women 
has  been reported by aAmah-Tariah et al.  2016 (Table 1). IgG1 is the most 
abundant IgG subclass in serum, and it appears during viral infections to initiate 
inflammatory responses (Einarsdottir et al., 2014; Kapur et al., 2014). Additionally, 
when specific protein antigens induce B cell activation in the presence of T-helper 
cells subclass switching may favor IgG1, to activate the classical complement 
pathway (Pone et al., 2010). Thus up-regulated IgG1 levels in our study may be 
conceivable.  
Nonetheless, HIV eventually cultivates a resistance to the complement pathway, 
by acquiring proteins derived from human cells (Huber et al., 2011). Despite the 
abundance of IgG in HIV infected pregnancies, the opsonized retrovirus 
ultimately infects macrophages and dendritic cells (Liu et al., 2004; Maartens et al., 
2014). This eventuates in  a surge of viral proteins and directs disease progression 
to AIDS development, because of the failure to control viral activity (Moir and 
Fauci, 2017). In our study, IgG2 was significantly down-regulated in HIV positive 
versus HIV negative pregnancies, irrespective of pregnancy type (Table 4). 
Notably, IgG3 and IgG4 levels were non-significantly down-regulated in HIV 
positive compared to HIV negative pregnancies, regardless of pregnancy type 
(Table 4). The decreased IgG2, IgG3 and IgG4 levels may be attributed to a 
combination of unspecific polyclonal B cell activation and impaired T-helper cell 
activity, or selective subclass switching (Vidarsson et al., 2014).  Additionally, 
HAART (the standard care for HIV infection in South Africa) is known to 
reconstitute immunity thus explaining the moderated IgG2, IgG3 and IgG4 
expression in our results (Iordache et al., 2017).   
In the current study, IgA levels were significantly down-regulated in HIV positive 
compared to HIV negative pregnancies (Table 4). In contrast, aAmah-Tariah et al. 
(2016) reported a significant increase in IgA levels in HIV positive compared to 
HIV negative pregnancies (Table 1). The neutralization mechanism of IgA 
induces the elimination of pathogens through phagocytosis, the release of 
cytokines and activated oxygen species, and antibody dependent cell-mediated 
cytotoxicity (Woof and Russell, 2011). This neutralizing capacity of IgA may 
account for high serum levels in HIV positive individuals. Alternatively, the 
significant down-regulation of IgA in our study may be ascribed to the mechanism 
of HAART in restoring immune levels.   
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In our study, IgM significantly declined in HIV infected pregnancies compared to 
HIV negative pregnancies (Table 4). The decrease in IgM may implicate failure  
to control viral activity and disease progression to AIDS, following the 
impairment of non-specific B cell activation. In dissimilarity, aAmah-Tariah et al. 
(2016) reported a significant increase of IgM in HIV positive pregnancies. 
However, previous studies have indicated that varying immunoglobulin levels 
could be an outcome of genetic and environmental variance in B cell response to 
HIV infection (Payne et al., 2007; Akinpelu et al., 2012). Furthermore, HAART 
endeavors to increase CD4+ cell counts, opposing disease progression and 
reconstituting immunity hence, validating the plausibility of our findings (Fiore 
et al., 2006; Maharaj et al., 2017).   
There is a paucity of information on the role of immunoglobulins in HIV 
associated PE, receiving HAART. It has been hypothesized, that HIV could 
counteract the exacerbated immune system response caused by PE, restoring 
immunoglobulin levels to that of normotensive HIV negative pregnancies (Mattar 
et al., 2004). This study demonstrates immunoglobulin concentrations across HIV 
positive, and HIV negative normotensive and preeclamptic pregnancies. We show 
that IgG1, IgG3, IgG4 and IgM express down-regulatory trends in HIV positive 
PE, albeit non-significantly (Table 5). It is plausible that regardless of the role of 
IgG subclasses in maternal-fetal passive immunity, the administration of HAART 
counteracts uncontrolled B cell activation and high immunoglobulin levels 
induced by HIV infection. However, IgG2 articulated an overall significant up-
regulation in HIV negative PE when compared to HIV negative normotensive, 
and HIV positive normotensive and preeclamptic pregnancies (Table 5). The 
distinctive response of this specific IgG subclass may be a result of specific 
antigen subclass switching, which promotes activation of classical complement 
by IgG2.   
Alternatively, we report  significantly higher levels of IgA in HIV negative PE, 
compared to all other study groups (Table 5). In healthy pregnancies devoid of 
viral infection, a suppressed maternal immune level is required for the 
continuation of pregnancy (Khirwadkar and Kher, 1991). During PE, IgA may act 
explicitly to inhibit the hyper-inflammatory response emanating from classical 
complement activation. This may be a result of IgA activating the lectin-mannose 
binding and alternative pathway, attempting to block the activation of the classical 
complement (Roos et al., 2006). The specific “blocking” effect implicates that 
IgA may cause a down-regulation of other immunoglobulins during PE, as both 
IgG and IgM are responsible for activating the classical complement  pathway. In 
addition, IgA also functions to neutralize pathogens like HIV through various 
elimination techniques (Kerr, 1990). Therefore, a significant up-regulation trend 
in serum IgA levels is associated with HIV infection (Mazzoli et al., 1999). 
However, the administration of HAART to HIV infected pregnant women, may 
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act to reduce elevated IgA levels stimulated by HIV infection. Therefore, IgA was 
significantly lower in HIV infected PE compared to HIV negative PE (Table 5).   
In conclusion we demonstrate the enhancement of IgG2 and IgA in the duality of 
PE and HIV infection. Our study predicts that whilst IgG2 is the least preferred 
IgG subclass in the maternal-fetal transfer of passive immunity, it is the preferred 
subclass to activate complement-mediated inflammatory responses in PE. In 
addition, it is plausible that IgA acts as an anti-inflammatory marker in the hyper-
inflammatory microenvironment of PE. In HIV infection, the down-regulation of 
IgG2, IgA and IgM may be attributed to HAART. The early detection of up-
regulated IgG2 and IgA in pregnancy may serve as a predictive test for PE 
development. However, further research on the natural anti-inflammatory 
response of IgA in PE may provide potential protection against the effects of PE. 
Moreover, the mechanism of IgG2 and IgA in HIV associated PE requires further 
exploration. 
 
Recommendations and Limitations  
These findings highlight the need for further investigation on the role of IgG 
subclasses and IgA inflammatory responses, in HIV infected preeclamptics on 
HAART. Further research on the anti-inflammatory effector functions of IgA in 
PE and HIV infected pregnancies are warranted. Limitations of our study include 
a small sample size. A larger sample size would enhance the understanding of the 
role of immunoglobulins in HIV associated PE.  
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In South Africa, maternal mortality is a serious public health concern. More than one third 
(34.7%) of maternal deaths in South Africa emanate from HIV infection in pregnancy (Saving 
mothers 2011–2013, 2014). In addition, PE is a major contributor of maternal mortality, 
accounting for 12% of all maternal deaths in South Africa (Saving mothers 2014–2016, 2017). 
Whilst some epidemiological findings associate PE with genetic and immunological factors, the 
etiology and pathogenesis of this hypertensive disorder remains a contentious dilemma (Khaliq 
et al., 2018). Furthermore, literature on the role of HAART in HIV associated PE are few. There 
is deliberation as to whether HIV infected women on HAART have a lower pre-disposition to 
obstetric complications, such as PE (Browne et al., 2015; Phoswa et al., 2018). The present study 
aimed to investigate the delicate immune balance that exists between HIV infected preeclamptics,  
on HAART. 
 
Healthy pregnancy is characterized by suppression of the  classical complement pathway, to deter 
immune responses against the fetus (Ahmad and Khidir, 2018). IgG and IgM bind to C1 
complexes of classical complement, prompting the activation of potent anaphylatoxins (C3a and 
C5a), suppressed pro-inflammatory cytokine production and elevated anti-inflammatory cytokine 
production (Nayak et al., 2010; Vidarrsson et al., 2014). The activation of complement proteins 
persuades cell lysis  through the infiltration of a moderated inflammatory cascade (Sarma and 
Ward, 2011). Corroborating this phenomenon, healthy pregnant women showed a significant 
down-regulation in IgG and IgA over three trimesters, whilst IgM decreased in the first and second 
trimesters when compared to non-pregnant women (Khirwadkar and Kher, 1991). However, 
during PE the immune system is further augmented, as elevated concentrations of complement 
proteins exist maternally (Derzy et al., 2013). The aberrant activation of complement proteins in 
PE is indicative of a hypertensive inflammatory cascade, which encourages an increased 
production of pro-inflammatory cytokines and neutrophils (Cornelius et al., 2018).  
 
Although, theoretically an increased IgG level would confirm the amplified inflammatory process 
that persists during PE, the precedence of fetal needs govern the maternal immune system through 
transplacental immunity (Fouda et al., 2018). The maternal-fetal transfer of immunoglobulins 
traverses the placenta and favors the IgG4, IgG3 and IgG1 subclasses, providing passive 
immunity in cumulative levels respectively (Schneider and Miller, 2009). The current study 
demonstrates a comparison of immunoglobulin levels between PE and normotensive pregnancies, 
irrespective of HIV status. IgG subclasses (IgG1, IgG3, and IgG4) presented a non-significant 
down-regulatory trend in PE. Nonetheless, Fialova et al. (2004),  Arinola et al. (2006) and bAmah-
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Tariah et al. (2016) reported a significant down-regulation in overall IgG levels in PE. In addition, 
we noted a non-significant up-regulated trend of IgG2 in preeclamptic pregnancies compared to 
normotensive pregnancies, irrespective of HIV status. Although the mechanism of maternal-fetal 
passive immunity favors IgG subclasses notably, the IgG2 subclass is the least favored form of 
immune transfer (Palmeira et al., 2011). Furthermore, IgG2 exists in trivial quantities in fetal sera 
thus explicating the current findings (Malek, 2013). Moreover, our findings allude to IgG2 being 
the preferred subclass in the activation of classical complement during PE. Alternatively, 
underlying bacterial infections with a specificity for polysaccharide antigens may distinctively 
prefer IgG2 antibodies, resulting in an increased B cell production of this subclass (Valenzuela 
and Schaub, 2018).  
 
Additionally, our study exhibits a non-significant up-regulatory trend in IgM levels, between 
preeclamptic versus normotensive pregnancies, regardless of HIV status. This observation is 
supported by Arinola et al. (2006) and Biró et al. (2007).  Nevertheless, bAmah-Tariah et al. 
(2016)  noted a significantly increased IgM level in PE. The IgM isotype is released as the first 
line of defense against pathogenic invasion in the human body (Boyden, 1966). In response to 
extraneous antigens, IgM stimulates the classical complement activation, to direct an 
inflammatory response against a plethora of pathogens (Baumgarth et al., 2005; Grönwall et al., 
2012). The up-regulated trend in IgM levels is anticipated, as PE is an exacerbated inflammatory 
response and IgM activates classical complement.  
 
Moreover, our study reported significantly higher levels of IgA in preeclamptic compared to 
normotensive pregnancies, irrespective of HIV status. Nonetheless, bAmah-Tariah et al. (2016) 
reported an up-regulation of IgA in preeclamptic diabetic pregnancies, compared to normotensive 
pregnancies, albeit non-significantly. However, whilst IgG subclasses and IgM activate the 
classical complement pathway, the role of IgA in complement remains abstruse. Some studies 
reported no participation of IgA in the complement pathway (Woof and Russell, 2011). However, 
a few studies report that IgA may inhibit activation of classical complement via the lectin and 
alternative pathways (Wolf et al., 1994). The latter is mediated through the binding of 
carbohydrate recognition receptors on mannose-binding lectin complexes (Matsuda, 1998; Roos 
et al., 2006). The activation of mannose-binding lectin to IgA is calcium dependent and activates 
C4 and C3  complement complexes (Dahl et al., 2000). In contrast, the alternative pathway is 
activated when IgA directly induces C3 activation, in a calcium- independent environment 
(Hiemstra et al., 1988; Holers, 2008). Activation of the lectin and alternative pathway alludes to 
IgA as a prohibitor of the hyperbolic inflammatory response by the immune system (Wilton, 1978; 
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Roos et al., 2006).  The impediment of classical complement is an attempt by IgA and the immune 
system to equipoise systemic hypertensive inflammatory responses, as seen in PE. Despite the 
hyper-inflammatory microenvironment related to PE, substantial proteinuria loss during PE may 
result in a significant reduction of IgA, as observed by Arinola et al. (2006).  
 
Furthermore, the role of immunoglobulins during HIV infected pregnancies on HAART, is 
perplexing. HIV infection causes a defect in T-helper cells and polyclonal B cell activation, 
ensuing a large IgG antigen pool (Huber et al., 2011). This may rationalize the upward trend in 
IgG1 levels noted in our study in HIV positive compared to HIV negative pregnancies, regardless 
of pregnancy type.  However, aAmah-Tariah et al. (2016) consequently observed a significant 
increase in overall IgG levels during HIV infected pregnancies, alluding to HIV disease 
progression to AIDS. 
 
Our study observed a significant down-regulation in IgG2 levels during HIV positive compared 
to HIV negative pregnancies, regardless of pregnancy type. Comparably,  IgG3 and IgG4 
communicated non-significant down-regulatory trends in HIV positive pregnancies. During HIV 
infection, activation of the complement system occurs, owing to the presence of HIV antigens 
(Huber et al., 2011). This systemic action is due to the virus directly activating the binding of 
viral envelope proteins to C1 complexes, in the absence of immunoglobulin-antigen complexes 
(Ebenbichler et al., 1991; Spear et al., 1991). Whilst virus infected cells cause complement 
activation, HIV has the unique ability as a retrovirus to use the complement system to prevent 
complement-mediated cell lysis of virions (Cooper et al., 2013; Moir and Fauci, 2017). This in 
turn provokes disease progression to AIDS, through increased dissemination and infectivity of 
the immunodeficiency virus (Huber et al., 2011; Maartens et al., 2014). The moderated levels of 
immunoglobulins in our study may concur with rapid disease progression to AIDS whereas, 
specific subclass switching favoring IgG1 may also be a causative factor to the overall reduction 
of immunoglobulins. Moreover, in South Africa, all HIV infected women receive anti-retroviral 
immune therapy (HAART), a standard care practice to reconstitute immunity (Iordache et al., 
2017; Phoswa et al., 2018). Notably, HAART may act to restrain  non-specific B cell activation 
and uncontrolled immunoglobulin production in HIV infections, validating the down-regulatory 
trends observed (Khan et al., 2016).  
 
In the current study, significantly down-regulated IgA and IgM levels in HIV positive pregnancies 
were noted when compared to HIV negative pregnancies. In variation, aAmah-Tariah et al. (2016) 
reported a significant increase in IgA and IgM levels during HIV infected pregnancies, compared 
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to HIV negative pregnancies. Up-regulated IgA levels in HIV infected individuals may be a result 
of specific neutralizing action against pathogens (Singh et al., 2014).  Interactions between IgA 
and FcὰRI present on neutrophils, eosinophils, monocytes, dendritic cells and some macrophages 
induce a neutralizing effect against HIV progression to AIDS (Lopez et al., 2018). Moreover, 
communication between IgA, the lectin and alternative complement pathways towards reducing 
increased inflammatory responses during acute HIV infection, may justify observations by 
aAmah-Tariah et al. (2016). In addition, the up-regulated IgM levels noted by aAmah-Tariah et 
al. (2016) suggest an increased inflammatory reaction to acute HIV infection. However, in our 
study HIV positive pregnancies receiving HAART, may have influenced the current down-
regulation trends in IgA and IgM. 
 
To further understand the role of immunoglobulins in HIV infected PE, our study analyzed isotype 
levels in HIV positive PE, HIV negative PE, HIV positive and negative normotensive 
pregnancies. We observed non-significant down-regulated IgG1, IgG3, IgG4 and IgM levels in 
HIV positive PE when compared to HIV positive normotensive, HIV negative normotensive and 
preeclamptic pregnancies. Despite immune processes that act to reject the developing fetus during 
pregnancy complications, down-regulatory trends in specific IgG subclasses (IgG1, IgG3 and 
IgG4) reiterate the pivotal role of the maternal-fetal immune transfer in PE (Palmeira et al., 2011). 
Conversely, the noted trend in IgG1, IgG3, IgG4 and IgM may be the outcome of HAART in HIV 
infected preeclamptic pregnancies.  
 
On the contrary, our study demonstrated the significant up-regulation of IgG2 in HIV negative 
PE, when compared to HIV negative normotensive, HIV positive normotensive and preeclamptic 
pregnancies. These findings are plausible due to specific antigen subclass switching to IgG2 
(Valenzuela and Schaub, 2018). In turn, subclass switching may act to promote IgG2 as an 
activator of the classical complement pathway during pregnancy. Furthermore, we noted a 
significant up-regulation of IgA in HIV positive PE, when compared to HIV positive 
normotensive, HIV positive and negative preeclamptic pregnancies. Whilst IgA has unique 
neutralizing abilities against pathogens, patients receiving HAART may endure the restraint of 
HIV, as HAART acts to counteract and restore immunity. Moreover, the inimitable anti-
inflammatory ability of IgA may act to possibly inhibit classical complement activation (Wolf et 
al., 1994). The transpired exaggerated inflammatory response from classical complement, may 
account for the up-regulated IgA levels in our study. 
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3.2 Conclusion  
Our study displays the reconstitution of IgG2, IgA and IgM in HIV positive pregnant women on 
HAART. Furthermore, we demonstrate the imperative role of IgG1, IgG3 and IgG4, whilst 
highlighting the function of IgG2 in the maternal-fetal transfer of immunoglobulins. Our results 
report an up-regulation of IgG2 in PE, suggesting that this specific subclass activates the classical 
complement pathway thus exaggerating the inflammatory cascade in PE. In our study, the up-
regulation of IgA indicates an anti-inflammatory response to the pathogenesis of PE. Moreover, 
the up-regulation of IgA in HIV positive PE implicates that immune reestablishment due to 
HAART may be deficient in stabilizing the exaggerated inflammatory response in PE. However, 
further research on a larger study population is required to understand the role of IgG2 as a pro-
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Regression Type: Logistic - 5PL 
Std. Curve: FI = 9.61305 + (20880.5 - 9.61305) / ((1 + (Conc / 206.409)^-1.13181))^0.889675 






Regression Type: Logistic - 5PL 
Std. Curve: FI = 3.49476 + (7522.71 - 3.49476) / ((1 + (Conc / 1247.14)^-2.2374))^0.486898 
FitProb. = 0.6582, ResVar. = 0.1958 
 
 
Regression Type: Logistic - 5PL 
Std. Curve: FI = -6.99762 + (25342.8 + 6.99762) / ((1 + (Conc / 77.4793)^-1.2075))^0.701453 





Regression Type: Logistic - 5PL 
Std. Curve: FI = 5.57927 + (22502.5 - 5.57927) / ((1 + (Conc / 24.3765)^-1.10428))^0.879445 




Regression Type: Logistic - 5PL 
Std. Curve: FI = 15.5966 + (20615.6 - 15.5966) / ((1 + (Conc / 12.603)^-1.07737))^1.46774 






Regression Type: Logistic - 5PL 
Std. Curve: FI = 4.93688 + (19978.2 - 4.93688) / ((1 + (Conc / 906.629)^-1.34072))^0.731065 
FitProb. = 0.1374, ResVar. = 1.8400 
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